<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Eggermont, Alexander M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Advances in Prospective and Innovative Randomized Clinical Trials</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6-8</style></pages><abstract><style  face="normal" font="default" size="100%">Precision medicine uses traditional and emerging concepts of the genetic and environmental basis of disease to individualize prevention, diagnosis and treatment [National Cancer Institute, 2011]. It integrates the tumor genetics of individual patients into medical practice. The potential value of the targeted and precise approach is great. This article discusses advances in precision medicine from the perspective of prospective clinical trials. A specific example of melanoma as a model for personalized cancer medicine is also presented.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>